Dyne Therapeutics Rings the Closing Bell
ABOUT THIS EVENT
Dyne Therapeutics (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, visits the Nasdaq MarketSite in Times Square to celebrate the recent start of clinical trials for its two lead programs and the two-year anniversary of its IPO.
In honor of the occasion, Joshua Brumm, President and Chief Executive Officer, and Dyne employees, ring the Closing Bell.